New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

SAN DIEGO--(BUSINESS WIRE)-- This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...

Sourced from the diabetes community at large through an open call earlier this year, the 16 selected advocates represent strength, advocacy and pride in living with Type 1, Type 2 and prediabetes ...

(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of the second season of ...

Dexcom reports 13% Q4 revenue growth to $1.26B, beating analyst expectations despite mixed analyst ratings and competitive pressures.

Dexcom's 2026 revenue estimates lagged analysts' expectations, according to data compiled by the London Stock Exchange Group ...

Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in ...